Purinergic Signaling and the Postmenopausal Heart

RECRUITING

I'm interested ...!!

There is an increased risk of diastolic heart failure in post menopausal women. Estrogen plays a positive role in regulating molecular pathways in heart remodeling. Such pathways may work through purinergic signaling and its downstream effects on the heart's mitochondrial metabolism and angiogenic response to stress. Loss of estrogen functionality in post menopausal women may account for the increased risk of diastolic heart failure. The investigators will explore said pathways using cardiac tissue obtained from patients undergoing cardiac surgery.

Conditions:

Diastolic Heart Failure Heart Failure With Preserved Ejection Fraction

Study Start (Actual) 2019-07-01

Primary Completion (Estimated) 2024-06

Study Completion (Estimated) 2024-06

Enrollment (Estimated) 100

Study Type OBSERVATIONAL

Phase N/A

Locations:

📍 Boston, Massachusetts, United States

Eligibility Criteria

Description

Inclusion Criteria:

* Patients undergoing cardiac surgery under cardiopulmonary bypass.

Exclusion Criteria:

* Refusal to participate
* Emergency surgery
* Pre-existing heart block
* Preexisting atrial fibrillation
* Redo surgery
* Estrogen or hormone replacement therapy
* History of chronic heart failure
* History of major kidney disease

Ages Eligible for Study: 30 Years to 88 Years (ADULT, OLDER_ADULT)

Sexes Eligible for Study: ALL

Accepts Healthy Volunteers: No

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

First Submitted2023-08-23
First Submitted that Met QC Criteria2023-08-28
First Posted2023-08-29

Study Record Updates

Last Update Submitted that Met QC Criteria2023-08-28
Last Update Posted2023-08-29
Last Verified2023-08